{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:35:39Z","timestamp":1753439739146,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05247-5","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T13:07:06Z","timestamp":1669813626000},"page":"559-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-5394","authenticated-orcid":false,"given":"Tatjana","family":"Zeki\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-9937","authenticated-orcid":false,"given":"Mirjana Stani\u0107","family":"Beni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"5247_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jfma.2020.04.004","volume":"120","author":"S Zhang","year":"2021","unstructured":"Zhang S, Wang L, Li M et al (2021) The PD-1\/PD-L pathway in rheumatic diseases. J Formos Med Assoc 120:48\u201359. https:\/\/doi.org\/10.1016\/j.jfma.2020.04.004","journal-title":"J Formos Med Assoc"},{"key":"5247_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"5247_CR3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3389\/fonc.2020.01644","volume":"10","author":"A Raimondi","year":"2020","unstructured":"Raimondi A, Sepe P, Zattarin E et al (2020) Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front Oncol 10:1644. https:\/\/doi.org\/10.3389\/fonc.2020.01644","journal-title":"Front Oncol"},{"key":"5247_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/fon.15.52","volume":"11","author":"JR Brahmer","year":"2015","unstructured":"Brahmer JR, Hammers H, Lipson EJ (2015) Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 11:1307\u20131326. https:\/\/doi.org\/10.2217\/fon.15.52","journal-title":"Future Oncol"},{"key":"5247_CR5","doi-asserted-by":"publisher","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","volume":"37","author":"H Ishihara","year":"2019","unstructured":"Ishihara H, Takagi T, Kondo T et al (2019) Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 37:355.e21-355.e29. https:\/\/doi.org\/10.1016\/j.urolonc.2019.03.003","journal-title":"Urol Oncol"},{"key":"5247_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/1574886313666180508122332","volume":"13","author":"D Benfaremo","year":"2018","unstructured":"Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A (2018) Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. Curr Drug Saf 13:150\u2013164. https:\/\/doi.org\/10.2174\/1574886313666180508122332","journal-title":"Curr Drug Saf"},{"key":"5247_CR7","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (2012) Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/) Accessed 5 August 2022"},{"key":"5247_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"5247_CR9","unstructured":"Pharmgkb (2021) Nivolumab: automated annotations. https:\/\/www.pharmgkb.org\/chemical\/PA166129522\/automatedAnnotation. Accessed 10 August 2022"},{"key":"5247_CR10","doi-asserted-by":"publisher","unstructured":"De Mattia E, Cecchin E, Guardascione M, et al (2019) Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol 25:3870\u20133896. https:\/\/doi.org\/10.3748\/wjg.v25.i29.3870https:\/\/www.wjgnet.com\/1007-9327\/full\/v25\/i29\/3870.htm. Accessed 22 October 2022","DOI":"10.3748\/wjg.v25.i29.3870"},{"key":"5247_CR11","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"5247_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","volume":"80","author":"M Kostine","year":"2021","unstructured":"Kostine M, Finckh A, Bingham CO et al (2021) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 80:36\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217139","journal-title":"Ann Rheum Dis"},{"key":"5247_CR13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.638526","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.638526","journal-title":"J Clin Oncol"},{"key":"5247_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160\u2013169. https:\/\/doi.org\/10.1159\/000455014","journal-title":"Am J Nephrol"},{"key":"5247_CR15","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S et al (2020) Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 126:4156\u20134167. https:\/\/doi.org\/10.1002\/cncr.33033","journal-title":"Cancer"},{"key":"5247_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bju.14461","volume":"123","author":"U De Giorgi","year":"2019","unstructured":"De Giorgi U, Carten\u00ec G, Giannarelli D et al (2019) Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int 123:98\u2013105. https:\/\/doi.org\/10.1111\/bju.14461","journal-title":"BJU Int"},{"key":"5247_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3325\/cmj.2020.61.326","volume":"61","author":"M Gamulin","year":"2020","unstructured":"Gamulin M, Nham E, Rkman D et al (2020) Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. Croat Med J 61:326\u2013332. https:\/\/doi.org\/10.3325\/cmj.2020.61.326","journal-title":"Croat Med J"},{"key":"5247_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.010","journal-title":"Eur J Cancer"},{"key":"5247_CR19","doi-asserted-by":"publisher","first-page":"8910","DOI":"10.18632\/oncotarget.13315","volume":"8","author":"R Costa","year":"2017","unstructured":"Costa R, Carneiro BA, Agulnik M et al (2017) Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 8:8910\u20138920. https:\/\/doi.org\/10.18632\/oncotarget.13315","journal-title":"Oncotarget"},{"key":"5247_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000486679","volume":"94","author":"K Zarrabi","year":"2018","unstructured":"Zarrabi K, Wu S (2018) Risk of liver toxicity with nivolumab immunotherapy in cancer patients. Oncology 94:259\u2013273. https:\/\/doi.org\/10.1159\/000486679","journal-title":"Oncology"},{"key":"5247_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL et al (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360:k793. https:\/\/doi.org\/10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"5247_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2217\/imt-2017-0174","volume":"10","author":"S Badovinac","year":"2018","unstructured":"Badovinac S, Korsic M, Zarkovic K et al (2018) Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer. Immunotherapy 10:427\u2013431. https:\/\/doi.org\/10.2217\/imt-2017-0174","journal-title":"Immunotherapy"},{"key":"5247_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","volume":"41","author":"F Angelopoulou","year":"2021","unstructured":"Angelopoulou F, Bogdanos D, Dimitroulas T et al (2021) Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int 41:33\u201342. https:\/\/doi.org\/10.1007\/s00296-020-04665-7","journal-title":"Rheumatol Int"},{"key":"5247_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102586","volume":"19","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Anquetil C, Manouchehri A et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586. https:\/\/doi.org\/10.1016\/j.autrev.2020.102586","journal-title":"Autoimmun Rev"},{"key":"5247_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2147\/TCRM.S308194","volume":"17","author":"F Grimaud","year":"2021","unstructured":"Grimaud F, Penaranda G, Stavris C et al (2021) Adverse events induced by PD-1\/PD-L1 inhibitors: a real-world single-centre experience with a management-based approach. Ther Clin Risk Manag 17:669\u2013677. https:\/\/doi.org\/10.2147\/TCRM.S308194","journal-title":"Ther Clin Risk Manag"},{"key":"5247_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nat Rev Clin Oncol"},{"key":"5247_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928390","volume":"12","author":"S Bruera","year":"2022","unstructured":"Bruera S, Suarez-Almazor ME (2022) The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol 12:928390. https:\/\/doi.org\/10.3389\/fonc.2022.928390","journal-title":"Front Oncol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05247-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T08:05:41Z","timestamp":1677312341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05247-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["5247"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05247-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"19 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This narrative review is written in compliance with ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}